BCL6 is a regulator of SOCS2, so less BCL6 leads to less SOCS2. At normal levels, this allows BCL6 to control how much SOCS2 is expressed, and therefore, how much IGF1 is made.

BCL6 regulates SOCS2, so a decrease in BCL6 leads to a drop in SOCS2. Under normal conditions, BCL6 ensures proper SOCS2 expression, which, in turn, controls the production of IGF1.

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) ...

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic ...

Arvinas to present preclinical data on ARV-393, a BCL6 degrader, at the EHA meeting in Milan, June 2025. Quiver AI Summary. Arvinas, Inc. announced that it will present new preclinical data on its ...

Deregulated BCL6 expression is common in B-cell lymphoma and promotes cancer cell survival, proliferation, and genomic instability. PROTAC-mediated degradation has the potential to address the ...

Bristol Myers Squibb presents data across targeted protein degradation research including CELMoD agents and BCL6 ligand-directed degrader at EHA 2025: Princeton, New Jersey Friday ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) ...

--Arvinas, Inc., a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical data for ARV-393 will be ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) ...

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic ...

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress. Arvinas Inc. Fri, Jun 13, 2025, 7:00 AM 6 min read.